Quantcast

Latest European Society for Medical Oncology Stories

2014-10-08 12:25:21

NORWALK, Conn., Oct. 8, 2014 /PRNewswire/ -- UBM Medica US announces that Cancer Network, a leading online community for oncologists and others who treat cancer and the online home of the journal ONCOLOGY, presents exclusive coverage of the European Society for Medical Oncology (ESMO) 2014 Congress, held September 26-30 in Madrid, Spain. Cancer Network offers blogs, podcasts, and news on the latest clinical findings and best practices in oncology. Highlights from this year's meeting coverage...

pregnancy and cancer
2014-09-29 02:30:13

European Society for Medical Oncology Presentations at ESMO 2014 examine the impact of in-utero exposure to chemotherapy and radiotherapy, the safety of lymph node biopsy in pregnancy, and the outcomes of unplanned pregnancy during cancer treatment Children who are exposed to chemotherapy or radiotherapy while in the womb suffer no negative impacts on mental or cardiac development, international studies presented at the ESMO 2014 Congress in Madrid have shown. "When chemotherapy is...

2014-09-29 08:30:18

BONN, Germany, September 29, 2014 /PRNewswire/ -- Newly published European Society for Medical Oncology (ESMO) clinical guidelines for the treatment of metastatic colorectal cancer (mCRC) endorse radioembolisation, specifically with Yttrium-90 resin microspheres, as a clinically proven technology to "prolong time to liver tumour progression" in mCRC patients who have failed to respond to available chemotherapy options. SIR-Spheres Y-90 resin microspheres, the lead...

roche
2014-09-29 05:16:14

Chuck Bednar for redOrbit.com - Your Universe Online Perjeta, a new breast cancer drug developed by Swiss pharmaceutical company Roche, has shown “unprecedented” success in extending the lives of patients in a clinical trial, according to research results released on Sunday. According to Andrew Pollack of the New York Times, patients who took the drug had a median survival period nearly 16 months longer than those in the control group – the longest time ever for a drug used as an...

2014-09-27 08:21:23

- Afinitor led to an unprecedented median overall survival of 44 months, which represents a clinically meaningful while not statistically significant improvement(1) EAST HANOVER, N.J., Sept. 27, 2014 /PRNewswire/ -- Novartis today presented final results on overall survival (OS) from a Phase III trial of Afinitor(®) (everolimus) tablets plus best supportive care (BSC) compared to placebo plus BSC in patients with well-differentiated advanced and progressive pancreatic...

2014-09-27 08:21:20

- Global winners selected for their unique research projects that have the potential to advance research for the personalized treatment of solid tumors ROCKLAND, Mass., Sept. 27, 2014 /PRNewswire/ -- EMD Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, today announced the winners of the first Grant for Oncology Innovation (GOI), who will receive grants totaling $1.3 million. The 2014 winners were formally announced at an awards ceremony coinciding with the annual...

2014-09-25 08:26:59

Analyses of PRiDe, a registry of 457 recurrent glioblastoma patients, show that patients treated with the NovoTTF(TM)-100A System at their first and second recurrences had median overall survivals of 20.0 and 8.5 months, respectively ST. HELIER, Jersey, Sept. 25, 2014 /PRNewswire/ -- Novocure, a commercial stage oncology company, announced today that survival and efficacy data from its U.S. patient registry will be presented at the European Society for Medical Oncology (ESMO) Meeting...

2014-09-25 04:22:01

LUGANO, Switzerland, September 25, 2014 /PRNewswire/ -- Helsinn Group, a company focused on building quality cancer care, today announces that Phase III data from the largest trial program of its kind to date in anamorelin, a novel, once-daily ghrelin receptor agonist in development for cancer-anorexia-cachexia (CACS) in non-small cell lung cancer will be presented at the 38th European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, in 2014. Cancer...

2014-09-25 04:21:59

CARDIFF, Wales, September 25, 2014 /PRNewswire/ -- Simbec-Orion Group Limited, ("Simbec-Orion" or the "Group"), the specialist global Contract Research Organisation (CRO) offering all phases of development in Europe, North America and Australia focused on early and late stage clinical development and a leader in oncology and orphan diseases, will attend the European Society for Medical Oncology (ESMO) 2014 Congress to be held September 26-30 in Madrid, Spain....

2014-09-24 16:26:34

THOUSAND OAKS, Calif., Sept. 24, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and its subsidiary Onyx Pharmaceuticals, Inc. today announced that they will host a summary webcast of Kyprolis(®) (carfilzomib) for Injection data presented at the European Society for Medical Oncology (ESMO) 2014 Congress on Monday, Sept. 29, 2014, at 1 p.m. PT. Pablo Cagnoni, M.D., president of Onyx Pharmaceuticals, Inc., along with clinical investigators, will participate in the call. In addition, they...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.